Clinical Utility of Decipher
Because Decipher can independently predict metastatic behavior in PCa
patients, clinicians can make preliminary treatment decisions by
differentiating between low and high-risk individuals, preferentially
treating those predicted with high GC scores 40. In
comparison, Gleason scores, PSA levels, and other qualitative features
of PCa do not adequately distinguish the risk of continued PCa
progression and thereby does not offer a proper identification of low
and high-risk PCa patients. By stratifying patients based on their GC
score, personal treatment can be subsequently established. Patients with
low GC scores do not necessitate aggressive PCa treatment options such
as postoperative radiation, but those with higher GC scores can
immediately be benefitted by aggressive secondary therapy when
identified44 45.